vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and John Marshall Bancorp, Inc. (JMSB). Click either name above to swap in a different company.
John Marshall Bancorp, Inc. is the larger business by last-quarter revenue ($16.8M vs $16.1M, roughly 1.0× Journey Medical Corp). John Marshall Bancorp, Inc. runs the higher net margin — 36.3% vs -7.8%, a 44.1% gap on every dollar of revenue. Over the past eight quarters, John Marshall Bancorp, Inc.'s revenue compounded faster (15.3% CAGR vs 11.0%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
John Marshall Bancorp, Inc. is a U.S.-based bank holding company that operates through its wholly owned subsidiary John Marshall Bank. It provides a full suite of commercial and consumer banking products including deposit accounts, commercial loans, residential mortgages, and personal financial services, primarily serving retail customers and small-to-mid-sized businesses across the U.S. Mid-Atlantic region.
DERM vs JMSB — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $16.8M |
| Net Profit | $-1.2M | $6.1M |
| Gross Margin | — | — |
| Operating Margin | -2.8% | — |
| Net Margin | -7.8% | 36.3% |
| Revenue YoY | 27.3% | — |
| Net Profit YoY | -182.0% | 26.8% |
| EPS (diluted) | $-0.04 | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $16.8M | ||
| Q4 25 | $16.1M | $16.4M | ||
| Q3 25 | $17.0M | $16.3M | ||
| Q2 25 | $15.0M | $15.4M | ||
| Q1 25 | $13.1M | $14.6M | ||
| Q4 24 | $12.6M | $14.3M | ||
| Q3 24 | $14.6M | $13.8M | ||
| Q2 24 | $14.9M | $12.6M |
| Q1 26 | — | $6.1M | ||
| Q4 25 | $-1.2M | $5.9M | ||
| Q3 25 | $-2.3M | $5.4M | ||
| Q2 25 | $-3.8M | $5.1M | ||
| Q1 25 | $-4.1M | $4.8M | ||
| Q4 24 | $1.5M | $4.8M | ||
| Q3 24 | $-2.4M | $4.2M | ||
| Q2 24 | $-3.4M | $3.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 82.3% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 56.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | -2.8% | 47.4% | ||
| Q3 25 | -9.0% | 42.2% | ||
| Q2 25 | -19.2% | 42.7% | ||
| Q1 25 | -25.3% | 42.4% | ||
| Q4 24 | 17.7% | 42.5% | ||
| Q3 24 | -19.8% | 38.8% | ||
| Q2 24 | -19.7% | 39.7% |
| Q1 26 | — | 36.3% | ||
| Q4 25 | -7.8% | 36.2% | ||
| Q3 25 | -13.6% | 33.2% | ||
| Q2 25 | -25.3% | 33.1% | ||
| Q1 25 | -31.0% | 32.9% | ||
| Q4 24 | 12.1% | 33.3% | ||
| Q3 24 | -16.3% | 30.7% | ||
| Q2 24 | -22.6% | 30.9% |
| Q1 26 | — | $0.43 | ||
| Q4 25 | $-0.04 | $0.41 | ||
| Q3 25 | $-0.09 | $0.38 | ||
| Q2 25 | $-0.16 | $0.36 | ||
| Q1 25 | $-0.18 | $0.34 | ||
| Q4 24 | $0.10 | $0.33 | ||
| Q3 24 | $-0.12 | $0.30 | ||
| Q2 24 | $-0.17 | $0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $150.2M |
| Total DebtLower is stronger | $25.3M | — |
| Stockholders' EquityBook value | $31.9M | $268.1M |
| Total Assets | $94.6M | $2.4B |
| Debt / EquityLower = less leverage | 0.79× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $150.2M | ||
| Q4 25 | $24.1M | $130.0M | ||
| Q3 25 | $24.9M | $163.6M | ||
| Q2 25 | $20.3M | $116.9M | ||
| Q1 25 | $21.1M | $169.1M | ||
| Q4 24 | $20.3M | $122.5M | ||
| Q3 24 | $22.5M | $177.2M | ||
| Q2 24 | $23.9M | $182.6M |
| Q1 26 | — | — | ||
| Q4 25 | $25.3M | $80.9M | ||
| Q3 25 | $25.2M | $80.9M | ||
| Q2 25 | $25.1M | $80.8M | ||
| Q1 25 | $25.0M | $80.8M | ||
| Q4 24 | $24.9M | $80.8M | ||
| Q3 24 | $19.8M | $80.8M | ||
| Q2 24 | $19.7M | $24.7M |
| Q1 26 | — | $268.1M | ||
| Q4 25 | $31.9M | $265.6M | ||
| Q3 25 | $25.9M | $259.7M | ||
| Q2 25 | $19.2M | $253.7M | ||
| Q1 25 | $21.5M | $253.0M | ||
| Q4 24 | $20.1M | $246.6M | ||
| Q3 24 | $10.9M | $243.1M | ||
| Q2 24 | $11.3M | $235.3M |
| Q1 26 | — | $2.4B | ||
| Q4 25 | $94.6M | $2.3B | ||
| Q3 25 | $85.2M | $2.3B | ||
| Q2 25 | $81.2M | $2.3B | ||
| Q1 25 | $85.0M | $2.3B | ||
| Q4 24 | $80.2M | $2.2B | ||
| Q3 24 | $64.0M | $2.3B | ||
| Q2 24 | $65.2M | $2.3B |
| Q1 26 | — | — | ||
| Q4 25 | 0.79× | 0.30× | ||
| Q3 25 | 0.97× | 0.31× | ||
| Q2 25 | 1.30× | 0.32× | ||
| Q1 25 | 1.16× | 0.32× | ||
| Q4 24 | 1.24× | 0.33× | ||
| Q3 24 | 1.81× | 0.33× | ||
| Q2 24 | 1.75× | 0.11× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-6.3M | $22.6M | ||
| Q3 25 | $-2.4M | $1.2M | ||
| Q2 25 | $-942.0K | $7.5M | ||
| Q1 25 | $-2.8M | $7.0M | ||
| Q4 24 | $2.2M | $17.3M | ||
| Q3 24 | $-1.2M | $1.4M | ||
| Q2 24 | $-5.2M | $10.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $22.0M | ||
| Q3 25 | — | $1.2M | ||
| Q2 25 | — | $7.4M | ||
| Q1 25 | — | $6.6M | ||
| Q4 24 | — | $16.8M | ||
| Q3 24 | — | $1.3M | ||
| Q2 24 | — | $10.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | 134.7% | ||
| Q3 25 | — | 7.3% | ||
| Q2 25 | — | 47.8% | ||
| Q1 25 | — | 45.3% | ||
| Q4 24 | — | 116.9% | ||
| Q3 24 | — | 9.5% | ||
| Q2 24 | — | 80.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.4% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 2.3% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 0.8% | ||
| Q2 24 | — | 0.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.82× | ||
| Q3 25 | — | 0.23× | ||
| Q2 25 | — | 1.48× | ||
| Q1 25 | — | 1.45× | ||
| Q4 24 | 1.46× | 3.61× | ||
| Q3 24 | — | 0.33× | ||
| Q2 24 | — | 2.60× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
JMSB
| Net Interest Income | $16.5M | 98% |
| Noninterest Income | $284.0K | 2% |
